Compare · ALPA vs DXCM
ALPA vs DXCM
Side-by-side comparison of Alpha Healthcare Acquisition Corp. III (ALPA) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALPA and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.18B, about 174.5x ALPA ($190.2M).
- DXCM has hit the wire 16 times in the past 4 weeks while ALPA has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 0 for ALPA).
- Company
- Alpha Healthcare Acquisition Corp. III
- DexCom Inc.
- Price
- $9.82-0.41%
- $89.79+2.13%
- Market cap
- $190.2M
- $33.18B
- 1M return
- -
- -0.10%
- 1Y return
- -
- +18.46%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2005
- News (4w)
- 0
- 16
- Recent ratings
- 0
- 25
Alpha Healthcare Acquisition Corp. III
Alpha Healthcare Acquisition Corp. III focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in New York, New York.
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest ALPA
- SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)
- SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)
- SEC Form SC 13G filed by Alpha Healthcare Acquisition Corp. III
- SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)
- SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)
- SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)
- SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)
- SEC Form SC 13G filed by Alpha Healthcare Acquisition Corp. III
- SEC Form SC 13G/A filed by Alpha Healthcare Acquisition Corp. III (Amendment)
- Alpha Healthcare Acquisition Corp. III filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest DXCM
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer
- EVP, Chief Financal Officer Sylvain Jereme M sold $302,936 worth of shares (3,638 units at $83.27) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 146,828 units (SEC Form 4)
- Director Boehnlein Glenn S was granted 5,841 shares (SEC Form 4)
- New insider Boehnlein Glenn S claimed ownership of 42 shares (SEC Form 3)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Appoints Glenn Boehnlein to Board of Directors
- Dexcom Announces Upcoming Conference Presentation